Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

Issue Brief: Assessing the impact of formulary exclusion on healthcare costs and outcomes for patients on therapy for certain chronic conditions

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Manufacturers

Optimize your pre-approval information exchange strategy

Medicare cannot age in place: A diversifying population requires policy evolution

Manufacturers

HTA Quarterly | Summer 2023

Manufacturers

HTA Quarterly | Winter 2022

Manufacturers

HTA Quarterly | Winter 2022

Closing the Gaps in Pre-Approval Information Exchange to Accelerate Product Success and Patient Access

Manufacturers

HTA Quarterly | Fall 2022

Upcoming cost-containing measures in Germany—How will they affect the biopharmaceutical industry?

Manufacturers

Market access abroad: Three reasons why early planning is critical for HTA countries

Skyrocketing growth in PBM formulary exclusions continues to raise concerns about patient access

Medicaid Best Price and Its Implications on Cell and Gene Therapy Products

Webinar: Debunking common PIE misperceptions to enhance your PIE strategy and tactics

The drug reimbursement environment in Canada: An overview

HTA Quarterly | Spring 2022

The UK Innovative Licensing and Access Pathway—A new paradigm in market access

Accelerated approval not accelerated access: Clinical trials required for coverage of Alzheimer's treatments

The impact of the Build Back Better Act (BBBA) on rare disease innovation

HTA Quarterly | Winter 2021

Is NICE becoming nicer?

340B – A missed opportunity to address those that are medically underserved

Health disparities and health technology assessment: Current value assessment frameworks fall short

Elucidating ICER’s methodologies for Unsupported Price Increase assessments  

Equity considerations in US value assessment: Opportunities ahead

Affordability is about more than drug prices

Copay accumulators and the impact on patients

Manufacturers

Strategies for addressing copay accumulators: What manufacturers need to know

The impact of obesity on COVID-19 outcomes of hospitalizations and mortality

It’s the Healthcare of the Future: Telehealth Trends Beyond 2020

Let's Ditch 2020 and Plan for 2021: Election What-Ifs

Impact of First Dollar Coverage for Insulin

Webinar: Navigating Pre-approval Information Exchange (PIE) and the AMCP Format for Formulary Submissions, Version 4.1

Impact of COVID-19 Pandemic on Patient Access Programs

Manufacturers

Mind the (Evidence) Gap

Effectively Communicating Pipeline Information to Drive Payers Attention